Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Friederike Zahm is active.

Publication


Featured researches published by Friederike Zahm.


Chemotherapy | 1988

In vitro Studies of Fleroxacin (Ro 23-6240), a New Trifluorinated Quinolone Derivative

Asbjørn Digranes; Eva Benonisen; Aud Salveson; Friederike Zahm

The in vitro activity of fleroxacin (Ro 23-6240) against 441 bacterial isolates was compared with those of ciprofloxacin, ofloxacin, amoxycillin, cefadroxil, cefuroxime and tobramycin. An agar dilution method was used for the determination of minimal inhibitory concentrations (MICs). Ciprofloxacin showed the highest activity against the Enterobacteriaceae, 95% of the isolates were inhibited by 0.06 mg/l, but fleroxacin and ofloxacin were also highly active (MIC 90% = 0.5 and 0.25 mg/l, respectively). Ciprofloxacin was the most active agent against Pseudomonas aeruginosa (MIC 90% = 0.12 mg/l), whereas the activities of fleroxacin and ofloxacin were more variable. Tobramycin was highly active against P. aeruginosa, 75% of the isolates were inhibited by 0.5 mg/l or less. The quinolones and tobramycin exhibited high activity against Acinetobacter calcoaceticus, the great majority of the isolates being susceptible to 0.5 mg/l or less of any agent. All the quinolones showed high activity against Staphylococcus aureus, but fleroxacin was less active against Staphylococcus epidermidis and Staphylococcus saprophyticus than were the other derivatives. The pneumococcal and streptococcal isolates were markedly less susceptible to fleroxacin than to the other quinolones tested (MIC range 4-32 mg/l). All isolates of Haemophilus influenzae and Neisseria gonorrhoeae were inhibited by the lowest concentration of the quinolones employed in the study (0.03 mg/l). Cefuroxime was also highly active against N. gonorrhoeae, whether the strains were beta-lactamase-producing or not, but was somewhat less active against H. influenzae. The quinolones displayed moderate and similar activity against Bacteroides fragilis isolates (MIC range 1-16 mg/l). The MICs of fleroxacin against gram-negative rods were generally 4-16 times higher at pH 8.8 than those obtained at pH 5.8 and 7.3. The activity against gram-positive cocci was not markedly influenced by changes in pH.


Hepatology | 1999

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a

Vicente Carreño; Patrick Marcellin; Stephanos J. Hadziyannis; Javier Salmerón; M. Diago; Geoge E. Kitis; Irene Vafiadis; Solko W. Schalm; Friederike Zahm; Félix Manzarbeitia; F. Javier Jiménez; Juan Antonio Quiroga


Archive | 1999

Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c

Friederike Zahm


Antiviral Research | 1999

In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

Julio Martı́n; Sonia Navas; Mario Fernández; Miguel Rico; Margarita Pardo; Juan Antonio Quiroga; Friederike Zahm; Vicente Carreño


Hepatology | 1999

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).

Carreño; Patrick Marcellin; Stephanos J. Hadziyannis; Javier Salmerón; M. Diago; Geoge E. Kitis; Irene Vafiadis; Solko W. Schalm; Friederike Zahm; Félix Manzarbeitia; Jiménez Fj; Juan Antonio Quiroga


Gastroenterology | 1994

Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a

Francesco Negro; Maurizio Baldi; Alessandra Mondardini; Gioacchino Leandro; Monique Chaneac; Paola Manzini; Maria Lorena Abate; Friederike Zahm; Giuseppe Dastoli; Marco Ballaré; Jean-Charles Ryff; Giorgio Verme


Hepatology | 1999

Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data

Calogero Cammà; Marco Giunta; Liliana Chemello; Alfredo Alberti; Hidenori Toyoda; Christian Trepo; Patrick Marcellin; Friederike Zahm; Solko W. Schalm; A. Craxì


Archive | 2001

Method for treating hepatitis C

Mary C. Graves; Stephen C. Pappas; Friederike Zahm


Hepatology | 1999

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).

Calogero Cammà; Marco Giunta; Liliana Chemello; Alfredo Alberti; Hidenori Toyoda; Christian Trepo; Patrick Marcellin; Friederike Zahm; Solko W. Schalm; A. Craxì


Antiviral Research | 2007

Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability

Klaus Klumpp; David Bernard Smith; Michael Brandl; Tom Alfredson; Keshab Sarma; Mark Smith; Isabel Najera; Wen-Rong Jiang; Sophie Le Pogam; Vincent Leveque; Han Ma; Yaping Tu; Rebecca Chan; Chiao-Wen Chen; Xiaoyang Wu; Raj Birudaraj; Steven Swallow; Joseph A. Martin; Nick Cammack; Heather Berns; Scott Fettner; Marie Mannino; Edward O’Mara; Carla Washington; Stuart K. Roberts; Graham Cooksley; Greg Dore; David Shaw; David R. Blue; Friederike Zahm

Collaboration


Dive into the Friederike Zahm's collaboration.

Top Co-Authors

Avatar

Solko W. Schalm

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Juan Antonio Quiroga

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

A. Craxì

University of Palermo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Javier Salmerón

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

M. Diago

University of Valencia

View shared research outputs
Researchain Logo
Decentralizing Knowledge